| Mrs Lillian Kay Satterfield, PN060590 | |
|
3134 Toledo Ave, Lorain, OH 44055-1430 | |
| (440) 246-2270 | |
| (440) 246-0185 |
| Full Name | Mrs Lillian Kay Satterfield |
|---|---|
| Gender | Female |
| Speciality | Licensed Vocational Nurse |
| Location | 3134 Toledo Ave, Lorain, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174695969 | NPI | - | NPPES |
| 2550967 | Other | OH | INDEPENDENT PROVIDER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 164X00000X | Licensed Vocational Nurse | PN-060590 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Lillian Kay Satterfield, PN060590 3134 Toledo Ave, Lorain, OH 44055-1430 Ph: (440) 246-2270 | Mrs Lillian Kay Satterfield, PN060590 3134 Toledo Ave, Lorain, OH 44055-1430 Ph: (440) 246-2270 |
News Archive
Scientists at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and colleagues at the University of Virginia in Charlottesville have succeeded in imaging, in unprecedented detail, the virus that causes influenza.
Quality sexual and reproductive health care is an essential component of public health. However, there are insufficient evidence-based policies related to adolescent sexual and reproductive health in low- and middle-income countries.
Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS).
Human papillomavirus (HPV) infection is the most common sexually transmitted infection in the United States, as well as a cause of various cancers, and a new study published online by JAMA Oncology estimates the overall prevalence of genital HPV infection in men ages 18 to 59.
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
› Verified 7 days ago